Anna-Maria Schmidmüller1, Irina Heid1, Jason G. Skinner2, Geoffrey J. Topping2, Katja Steiger3,5, Simon Baller1, Wolfgang Gottwald2, Franz Schilling2, Rickmer Braren1,4

Link to the paper

Department: 

Research Area C6

Abstract: 

Pancreatic ductal adenocarcinoma (PDAC) is a highly heterogeneous disease with poor prognosis and a high mortality rate1. Due to early metastatic spread, most PDAC patients are not eligible for surgery and instead receive palliative chemotherapy-based treatment. Here, we aim to examine changes in tumor metabolism caused by Gemcitabine/Abraxane, a standard of care, using a complex endogenous murine
PDAC model2 and a 3D balanced steady-state free precession (bSSFP)3 MR imaging of hyperpolarized (HP)v[1-13C]pyruvate and its metabolite [1-13C]lactate.